摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苯基-2-吡咯烷酮 | 1198-97-6

中文名称
4-苯基-2-吡咯烷酮
中文别名
4-苯基-2-吡咯酮;苯基-2-吡咯烷酮
英文名称
4-phenylpyrrolidin-2-one
英文别名
4-phenyl-2-pyrrolidinone;4-Phenyl-2-pyrrolidone
4-苯基-2-吡咯烷酮化学式
CAS
1198-97-6
化学式
C10H11NO
mdl
MFCD01687226
分子量
161.203
InChiKey
HOJZEMQCQRPLQQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    72.0~78.0℃
  • 沸点:
    287.51°C (rough estimate)
  • 密度:
    1.0840 (rough estimate)
  • 溶解度:
    可溶于氯仿(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933790090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    存储温度为0-10°C;应存放在惰性气体中;避免接触湿气(可能导致分解),并远离加热源。

SDS

SDS:f289d16f93b07014f0cfe2e352b3c166
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Phenyl-2-pyrrolidone
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Phenyl-2-pyrrolidone
CAS number: 1198-97-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11NO
Molecular weight: 161.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

  • 作为反应物:
    描述:
    4-苯基-2-吡咯烷酮 、 sodium hydride 作用下, 以 甲醇 为溶剂, 反应 11.0h, 生成 4-苯基-2-吡咯烷酮-1-乙酰胺
    参考文献:
    名称:
    4-苯基吡咯烷酮-2-乙酰胺的合成及解痉活性
    摘要:
    众所周知 [i] 各种化合物的解痉特性经常与结构元素的存在有关,这些结构元素包括一个苯基或一个苯环,这些元素相对于一个酰胺基团特别取向,通常是一个片段杂环系统(巴比妥酸、乙内酰脲、吡唑烷二酮、琥珀酰亚胺等)。pyrrolidone-2 的苯基衍生物满足这些要求,事实上,在 5-phenylpyrrolidone-2 的衍生物中发现了具有解痉活性的化合物 [2]。因此,4-苯基吡咯烷酮-2 的衍生物可能显示出明确的解痉作用,正如所指出的,它是苯基替代物 2-吡咯烷酮中在一些其他药理学特性中最活跃的 [3]。
    DOI:
    10.1007/bf00765621
  • 作为产物:
    描述:
    亚苯甲基丙二酸二乙酯 在 palladium on activated charcoal 盐酸氢气三乙胺 作用下, 以 甲醇甲苯 为溶剂, 60.0 ℃ 、275.79 kPa 条件下, 生成 4-苯基-2-吡咯烷酮
    参考文献:
    名称:
    Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogs
    摘要:
    Rolipram [(R,S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone] has been shown to inhibit selectively the cAMP phosphodiesterase (PDE) of vascular smooth muscle. In order to further explore the structural requirements for selective PDE inhibition, we synthesized a series of rolipram derivatives differently substituted either at the pyrrolidinone or at the aromatic ring. Among these compounds, rolipram was the most active compound. Semirigid analogues were prepared and used for an evaluation of the active conformation of rolipram. Structural comparison with two other potent and chemically different smooth muscle cAMP-PDE inhibitors, trequinsin and Ro 20-1724, allows us to propose a first topological model of the smooth muscle cAMP-PDE pharmacophore.
    DOI:
    10.1021/jm00127a009
点击查看最新优质反应信息

文献信息

  • [EN] 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)<br/>[FR] DÉRIVÉS DE 4-HYDROXYPIPÉRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROTÉASE 19 SPÉCIFIQUE DE L'UBIQUITINE
    申请人:ALMAC DISCOVERY LTD
    公开号:WO2019150119A1
    公开(公告)日:2019-08-08
    Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.
    提供了公式(I)的泛素特异性蛋白酶19(USP19)的抑制剂,以及包含该抑制剂的药物组合物,以及其使用方法。这些化合物可用于治疗肌肉萎缩、肥胖、胰岛素抵抗或2型糖尿病,或减少肌肉质量的流失。
  • GSK-3BETA INHIBITOR
    申请人:Kori Masakuni
    公开号:US20110039893A1
    公开(公告)日:2011-02-17
    For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA): wherein each symbol is as defined in the specification. or a salt thereof or a prodrug thereof.
    为了提供一种含有2-氨基吡啶化合物或其盐或其前药的GSK-3β抑制剂,用作GSK-3β相关病理或疾病的预防或治疗剂,本发明提供了一种含有由下式(IA)表示的化合物的GSK-3β抑制剂: 其中每个符号如规范中定义。 或其盐或其前药。
  • PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
    申请人:Philippe Michel
    公开号:US20100028280A1
    公开(公告)日:2010-02-04
    The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.
    该发明涉及一种直发角蛋白纤维的拉直过程,包括:(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤,(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
  • [EN] HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES D'HYDROXYETHYLAMINE UTILISES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
    申请人:GLAXO GROUP LTD
    公开号:WO2004050619A1
    公开(公告)日:2004-06-17
    The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated - amyloid levels or -amyloid deposits, particularly Alzheimer's disease.
    本发明涉及具有Asp2(-分泌酶,BACE1或Memapsin)抑制活性的新型羟乙基胺化合物的化学式(I):(I),其制备方法,含有它们的组合物以及它们在治疗由高β-淀粉样蛋白平或β-淀粉样蛋白沉积所特征的疾病中的应用,特别是阿尔茨海默病。
  • A phase-switch purification approach for the expedient removal of tagged reagents and scavengers following their application in organic synthesis
    作者:Jason Siu、Ian R. Baxendale、Russell A. Lewthwaite、Steven V. Ley
    DOI:10.1039/b503778f
    日期:——
    In this paper we wish to report on a variety of expedient chemical transformations and purifications achieved via a generic ‘catch and release’ methodology, based on a synthetically inert bipyridyl chelating tag that can be selectively captured with a resin-bound copper(II) species. Utilising this approach we are able to derive many of the same benefits associated with both solid phase synthesis and supported reagent methods.
    本文旨在报道通过一种基于合成不活跃的双吡啶螯合标签的通用“捕获与释放”方法,实现的一系列便捷的化学转化和纯化。该方法可以选择性地利用树脂结合的(II)物种来捕获双吡啶螯合标签。采用这种方法,我们能够获得与固相合成和支持试剂法相关的许多相同益处。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
cnmr
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基酰肼盐酸盐 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG6-丙酸 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-四聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-六聚乙二醇-羧酸 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-八聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式草酸双(-3,8-二氮杂双环[4.2.0]辛烷-8-羧酸叔丁酯) 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式4-氟吡咯烷酮-3-醇盐酸盐 顺式3,4-二羟基吡咯烷盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-5-甲基-1H-六氢吡咯并[3,4-b]吡咯二盐酸盐 顺式-5-氧代六氢环戊二烯并[c]吡咯-2(1H)-羧酸叔丁酯 顺式-5-乙氧羰基-1H-六氢吡咯并[3,4-B]吡咯盐酸盐 顺式-5-(碘甲基)-4-苯基-2-吡咯烷酮 顺式-5-(碘甲基)-4-甲基-2-吡咯烷酮 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-1-甲基六氢吡咯并[3,4-b]吡咯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁